Taysha Gene Therapies, Inc. (TSHA) intrinsic value & 10-year financials
Taysha Gene Therapies, Inc. (TSHA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 57.5% a year to $9.8M, with an average return on invested capital of 924.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.62
- Market cap
- $1.2B
- Revenue (FY2025)
- $9.8M
- Revenue growth (7-yr CAGR)
- 57.5%
- ROIC (10-yr avg)
- 924.1%
- Free cash flow (FY2025)
- -$93.8M
TSHA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $9.8M | -$109.0M | -$0.34 | -$93.8M | -1130.6% | 2129.1% |
| FY2024 | $8.3M | -$89.3M | -$0.36 | -$81.6M | -1097.6% | 1253.5% |
| FY2023 | $15.5M | -$111.6M | -$0.96 | -$76.9M | -468.8% | 400.7% |
| FY2022 | $2.5M | -$166.0M | -$3.78 | -$109.0M | -6492.7% | 739.7% |
| FY2021 | — | -$174.5M | -$4.64 | -$132.3M | — | 1055.9% |
| FY2020 | — | -$60.0M | — | -$30.8M | — | -34.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Taysha Gene Therapies, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Taysha Gene Therapies, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.6% ROIC.
Taysha Gene Therapies, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Taysha Gene Therapies, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.29 per share.